Oxcarbazepine Suspension
Product Images NDC 72162-2631

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 72162-2631). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622631)

Label for Oxcarbazepine oral suspension USP, 300 mg/5 mL, in a 250 mL container. The label includes storage instructions, dosage guide QR codes, and warnings to keep out of reach of children. Relabeled by Bryant Ranch Prepack, Inc., and manufactured by Medley Pharmaceuticals Ltd. The NDC code displayed is 72162-2631-2.*

FDA Label Image

Oxcar-12 (Oxcar 12)

A Kaplan-Meier survival curve showing exit rates over time (days) for two treatment groups labeled 'HIGH' and 'LOW'. The graph includes a log-rank test p-value of 0.0001, indicating statistical comparison between the groups.*

FDA Label Image

Oxcar-14 (Oxcar 14)

Oxcarbazepine 300 mg/5 mL oral suspension in a plastic cup container with a single compartment and a round opening at the top. The container is designed for single-dose administration and is labeled by Bryant Ranch Prepack.*

FDA Label Image

Oxcar-15 (Oxcar 15)

Oxcarbazepine oral suspension bottle with a child-resistant white cap. The bottle is opaque and rectangular with rounded edges, commonly used for liquid medications. No visible label text or additional details are shown in the image.*

FDA Label Image

Oxcar-16 (Oxcar 16)

An instructional diagram of an oral dosing syringe showing a barrel with volume markings up to 10 mL and a plunger. The barrel and plunger are labeled to indicate their parts.*

FDA Label Image

Oxcar-17 (Oxcar 17)

An instructional illustration showing a hand holding and shaking an oral suspension bottle. The bottle is tilted, and motion lines indicate shaking, likely demonstrating how to prepare the medication before use.*

FDA Label Image

Oxcar-18 (Oxcar 18)

An instructional illustration showing how to open a bottle by breaking the tamper-evident seal at the bottle neck, with hands twisting off the cap. The bottle and cap are both visible, indicating bottle opening steps.*

FDA Label Image

Oxcar-19 (Oxcar 19)

Illustration showing a hand holding and shaking an oral suspension bottle. This image visually represents proper handling or preparation of the medication prior to use, specifically for the oxcarbazepine 300 mg/5 mL oral suspension by Bryant Ranch Prepack.*

FDA Label Image

Oxcar-20 (Oxcar 20)

An instructional black-and-white illustration showing hands holding an oral suspension bottle and a syringe, with an arrow indicating the syringe being inserted into the bottle for medication withdrawal. The image relates to the proper method of drawing Oxcarbazepine oral suspension.*

FDA Label Image

Oxcar-21 (Oxcar 21)

An instructional line drawing showing the method to measure liquid medication. A hand is holding a measuring syringe under a bottle of oral suspension, with an arrow indicating to pull the syringe downward to draw the liquid. This diagram relates to dosing or administration guidance for an oral suspension product.*

FDA Label Image

Oxcar-22 (Oxcar 22)

An instructional diagram showing the administration of a liquid medication from a bottle into an oral dosing syringe. The image emphasizes the measurement of the dose, depicted as 8 mL on the syringe scale, with an arrow indicating the direction to draw the medication into the syringe.*

FDA Label Image

Oxcar-23 (Oxcar 23)

An instructional illustration shows a hand holding a syringe and drawing liquid medicine from a bottle by twisting or pulling the syringe plunger. The orientation suggests proper technique for measuring or administering an oral suspension.*

FDA Label Image

Oxcar-24 (Oxcar 24)

An instructional illustration showing a person administering oral suspension medication using a syringe and a separate image of the syringe being filled with the suspension from a container into a cup. This visual likely demonstrates how to measure and give Oxcarbazepine suspension orally.*

FDA Label Image

Oxcarb-10 (Oxcarb 10)

A line chart comparing the seizure rate over time (days from first dose to first seizure) between two treatment groups: Oxcarbazepine and Placebo. The x-axis represents the days from first dose to first seizure, and the y-axis represents the seizure rate. A p-value from a log-rank test (0.046) is shown on the chart.*

FDA Label Image

Oxcarb-11 (Oxcarb 11)

A Kaplan-Meier survival curve comparing time to exit for two treatment groups labeled as HIGH and LOW. The y-axis represents the exit rate from 0 to 1, and the x-axis shows time to exit in days up to 130. The chart includes a log-rank test p-value of 0.0001 indicating statistical comparison between groups.*

FDA Label Image

Oxcarbazepine-9 (Oxcarb 9)

A Kaplan-Meier survival curve graph showing exit rates on the y-axis and time on trial in days on the x-axis from Day 2 to Day 11. It compares two groups: Oxcarbazepine and Placebo, indicating differences in exit rates over time with a reported log-rank test p-value of 0.0001.*

FDA Label Image

Oxcarbazepine-fig1 (Oxcarbazepine 1)

A data table showing dosing ranges in mg/day based on patient weight in kilograms. It lists weight increments from 20 to 70 kg and corresponding 'From Dose' and 'To Dose' ranges in mg/day for each weight category.*

FDA Label Image

Oxcarbazepine-7 (Oxcarbazepine 7)

Chemical structure of Oxcarbazepine, showing its molecular framework including a keto group and an amide substituent attached to a dibenzazepine core.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.